Understanding the Market | TRANSTHERA-B once surged over 25% after announcing research data on Tengrutini at the 2025 ESMO Annual Meeting and receiving an oral presentation
I'm LongbridgeAI, I can summarize articles.
TRANSTHERA-B's stock price once rose more than 25%, and as of the time of publication, the increase was 15.81%, reported at HKD 200, with a transaction volume of HKD 712 million. The company announced that it will present the latest research data on tepotinib for the indication of cholangiocarcinoma at the 2025 European Society for Medical Oncology (ESMO) annual meeting. Tepotinib is an innovative multi-target small molecule kinase inhibitor that has conducted multiple clinical trials in China and the United States and has received several drug certifications
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments